Guardant Health, Inc. (GH)
NASDAQ: GH · IEX Real-Time Price · USD
33.00
+1.07 (3.35%)
Jul 26, 2024, 4:00 PM EDT - Market closed
Guardant Health Revenue
Guardant Health had revenue of $168.49M in the quarter ending March 31, 2024, with 30.90% growth. This brings the company's revenue in the last twelve months to $603.73M, up 25.21% year-over-year. In the year 2023, Guardant Health had annual revenue of $563.95M with 25.45% growth.
Revenue (ttm)
$603.73M
Revenue Growth
+25.21%
P/S Ratio
6.69
Revenue / Employee
$339,362
Employees
1,779
Market Cap
4.04B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Perrigo Company | 4.56B |
Integer Holdings | 1.63B |
Sotera Health Company | 1.08B |
Waystar Holding | 824.72M |
Inspire Medical Systems | 660.91M |
Ultragenyx Pharmaceutical | 442.59M |
Axsome Therapeutics | 251.02M |
Merus | 38.34M |
GH News
- 2 days ago - Guardant Health to Report Second Quarter 2024 Financial Results on August 7, 2024 - Business Wire
- 3 days ago - Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-in-Class Performance - Business Wire
- 8 days ago - Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors - Business Wire
- 7 weeks ago - Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer - Business Wire
- 2 months ago - Guardant Health Named to TIME100 Most Influential Companies - Business Wire
- 2 months ago - Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening - Business Wire
- 2 months ago - FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option - Business Wire
- 2 months ago - U.S. FDA advisers back approval for Guardant's blood-based cancer test - Reuters